Thank you DebKCardsPA

For additional reading on apabetalone/BRD3 inhibition/ABCA1 regulation, and the multiple cancers it may be useful for, here's what I have collected thus far:

(apologies for formatting)

OVARIAN CANCER (Chemotherapy resistant)

https://cdrjournal.com/article/view/3918

Results: High ABCA1 mRNA and protein expression was found to be significantly associated with poor patient outcome. ABCA1 mRNA and protein levels were significantly increased in ovarian cancer cell lines (OVCAR-5 CBPR and CaOV3 CBPR) with acquired carboplatin resistance. ABCA1 mRNA was significantly increased in primary HGSOC cells obtained from patients with acquired chemotherapy resistance. Apabetalone treatment reduced ABCA1 protein expression and increased the sensitivity of both parental and carboplatin-resistant ovarian cancer cells to carboplatin.

https://www.nature.com/articles/s41416-021-01321-0

COLORECTAL CANCER

March 2021

https://www.mdpi.com/1422-0067/22/7/3352/pdf

https://www.nature.com/articles/s41416-021-01321-0

HDL angle: https://www.mdpi.com/1422-0067/22/7/3352/htm

September 2018

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166002/

https://www.ncbi.nlm.nih.gov/pubmed/30098223

https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12367

https://www.mdpi.com/2072-6694/11/8/1097/htm

A recent study showed that human colon adenocarcinoma (CA) cells stably transfected with ABCA1, exhibit increased proliferative, invasive and migratory behavior, which could be inhibited by simultaneous, transgenic overexpression of ApoA-I, or by exogenous treatment with human recombinant ApoA-I [157]. This inhibition was associated with downregulation of cyclooxygenase 2 (COX-2), a known promoter of colon adenocarcinoma involved in proinflammatory processes. In the same study, apabetalone, a small molecule BET-inhibitor, used in experimental therapeutics of atherosclerosis and known to induce production of ApoA-I, reduced the ABCA1-driven proliferative and invasive behavior of CA cells [157]. Another study showed that treatment of CA cells with the ApoA-I-mimetic peptide L-4F induced G0/1 cell cycle arrest, associated with decreased expression levels of cyclins D1 and A and decreased cell viability [158]. Also, it reduced the survival of CA cells stimulated by lysophosphatidic acid (LPA), a potent bioactive phospholipid, known to decrease its free concentration in the cell culture media [158]. 

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/712700-abca1-overexpression-worsens-colorectal-cancer-prognosis-and-this-can-be-ameliorated-by-apabetalone/messages/2202805#message

This is a Spanish study in which the authors propose that the upregulation of ApoA-1 by apabetalone is reponsible for reduced malignancy in colorectal cancer cells. 

"Based on these results, we propose here, for the first time, the potential use of apabetalone, a stimulator of APOA1 so far only considered for CVD, as a bona fide inhibitor of colorectal cancer invasiveness."

 https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12367

PROSTATE CANCER

https://www.pharmaceutical-technology.com/comment/epigenetics-and-cancer/

LUNG CANCER

Cantos trial

https://pace-cme.org/2019/05/28/effect-of-il-1-inhibition-on-lung-cancer-sheds-new-light-on-the-role-of-inflammation/

LIVER CANCER  (hepatocellular carcinoma )

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy

https://www.future-science.com/doi/pdf/10.4155/fsoa-2018-0115

BRD3 inhibitors (RVX-208) 

BRD3 is primarily involved in recruiting GATA1 to chromatin in hematopoietic cells and regulating differentiation of erythroid, megakaryocyte and mast cell lineages. BRD3 inhibitors have not been extensively studied. However, pan-BET inhibitors such as JQ1 and I-BET151 have been observed to target BRD3 in NMC and leukemia. RVX-208, a derivative of the plant polyphenol resveratrol, binds to BD2 of BRD3 [84] and upregulates ApoA1 which plays an important role in hepatocellular carcinoma. Given that JQ1 strongly upregulates ApoA1 in HepG2 cells, it can be used in combination with RVX-208 as a multitarget inhibitor in hepatocellular carcinoma [85]